Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

• DOI: 10.2337/diacare.22.1.119
• Publication Date: 2007-03-05T22:51:27Z
• Authors: R Moses; R Slobodniuk; S Boyages; S Colagiuri; W Kidson; J Carter; T Donnelly; P Moffitt; H Hopkins
• Keywords: Repaglinide; Nateglinide

OBJECTIVE: To compare the effect of repaglinide in combination with metformin monotherapy each drug on glycemic control patients type 2 diabetes. RESEARCH DESIGN AND METHODS: A total 83 diabetes who had inadequate (HbA1c > 7.1%) when receiving antidiabetic agent were enrolled this multicenter, double-blind trial. Subjects randomized to continue their prestudy dose (n = 27), addition or receive alone 29). For repaglinide, optimal was determined during a 4- 8-week titration and continued for 3-month maintenance period. RESULTS: In subjects combined therapy, HbA1c reduced by 1.4 +/- 0.2%, from 8.3 6.9% (P 0.0016) fasting plasma glucose 2.2 mmol/l 0.0003). No significant changes observed treated either (0.4 0.3% decrease, respectively) (0.5 increase 0.3 decrease respectively). metformin, an levels insulin between baseline end trial 4.04 1.56 4.23 1.50 mU/l, respectively < 0.02). Gastrointestinal adverse events common group. An body weight occurred therapy groups (2.4 0.5 3.0 kg, respectively; P 0.05). CONCLUSIONS: Combined resulted superior compared whose glycemia not been well controlled alone. Repaglinide as effective monotherapy.